Review Article

Drugs

, Volume 66, Issue 3, pp 321-340

Mitomycin

Clinical Applications in Ophthalmic Practice
  • Lekha M. AbrahamAffiliated withDepartment of Ophthalmology and Visual Sciences, Royal Adelaide Hospital, University of Adelaide
  • , Dinesh SelvaAffiliated withDepartment of Ophthalmology and Visual Sciences, Royal Adelaide Hospital, University of AdelaideDepartments of Medicine and Surgery, University of Adelaide
  • , Robert CassonAffiliated withDepartment of Ophthalmology and Visual Sciences, Royal Adelaide Hospital, University of Adelaide
  • , Igal LeibovitchAffiliated withDepartment of Ophthalmology and Visual Sciences, Royal Adelaide Hospital, University of Adelaide Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Mitomycin (mitomycin C; MMC) is an antibiotic isolated from Streptomyces caespitosus. The drug is a bioreductive alkylating agent that undergoes metabolic reductive activation, and has various oxygen tension-dependent cytotoxic effects on cells, including the cross-linking of DNA. It is widely used systemically for the treatment of malignancies, and has gained popularity as topical adjunctive therapy in ocular and adnexal surgery over the past 2 decades.

In ophthalmic medicine, it is principally used to inhibit the wound healing response and reduce scarring of surgically fashioned ostia. Hence, it has been used as adjunctive therapy in various ocular surgeries, such as glaucoma filtering surgeries, dacryocystorhinostomy, corneal refractive surgery and surgeries for ocular cicatrisation. In addition, it has been used as an adjunct in the surgical management of pterygia, ocular surface squamous neoplasia, primary acquired melanosis with atypia and conjunctival melanoma. In many of these surgeries and ophthalmic pathologies, MMC showed a significant beneficial effect.